(Q40342245)

English

A DNA vaccine candidate encoding the structural prM/E proteins elicits a strong immune response and protects mice against dengue-4 virus infection

scientific article published on 27 November 2010

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

19 September 2017

A DNA vaccine candidate encoding the structural prM/E proteins elicits a strong immune response and protects mice against dengue-4 virus infection (English)

1 reference

Europe PubMed Central

19 September 2017

0 references

Danielle Malta Lima

object named as

Danielle Malta Lima

1

0 references

author name string

Sérgio Oliveira de Paula

2

1 reference

Europe PubMed Central

19 September 2017

Rafael Freitas de Oliveira França

3

1 reference

Europe PubMed Central

19 September 2017

Patrícia V B Palma

4

1 reference

Europe PubMed Central

19 September 2017

Fabiana R Morais

5

1 reference

Europe PubMed Central

19 September 2017

Alessandra Cristina Gomes-Ruiz

6

1 reference

Europe PubMed Central

19 September 2017

Maria Teresa Prudente de Aquino

7

1 reference

Europe PubMed Central

19 September 2017

Benedito Antonio Lopes da Fonseca

8

1 reference

Europe PubMed Central

19 September 2017

language of work or name

0 references

publication date

27 November 2010

1 reference

Europe PubMed Central

19 September 2017

1 reference

Europe PubMed Central

19 September 2017

29

1 reference

Europe PubMed Central

19 September 2017

4

1 reference

Europe PubMed Central

19 September 2017

831-838

1 reference

Europe PubMed Central

19 September 2017

Pathogenesis of dengue: challenges to molecular biology

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.10.078

7 January 2021

Dengue: emergence as a global public health problem and prospects for control

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.10.078

7 January 2021

Mosquito-borne Diseases

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.10.078

7 January 2021

Vaccine development against dengue and Japanese encephalitis: report of a World Health Organization meeting

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.10.078

7 January 2021

A plasmid encoding parts of the dengue virus E and NS1 proteins induces an immune response in a mouse model.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.10.078

7 January 2021

Development of a live attenuated dengue virus vaccine using reverse genetics

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.10.078

7 January 2021

Modification of dengue virus strains by passage in primary dog kidney cells: preparation of candidate vaccines and immunization of monkeys.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.10.078

7 January 2021

Construction, safety, and immunogenicity in nonhuman primates of a chimeric yellow fever-dengue virus tetravalent vaccine

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.10.078

7 January 2021

Immunogenicity and safety of two live-attenuated tetravalent dengue vaccine formulations in healthy Australian adults.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.10.078

7 January 2021

Fusion PCR generated Japanese encephalitis virus/dengue 4 virus chimera exhibits lack of neuroinvasiveness, attenuated neurovirulence, and a dual-flavi immune response in mice

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.10.078

7 January 2021

Live attenuated tetravalent dengue vaccine

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.10.078

7 January 2021

rDEN2/4Delta30(ME), a live attenuated chimeric dengue serotype 2 vaccine is safe and highly immunogenic in healthy dengue-naïve adults.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.10.078

7 January 2021

Live attenuated chimeric yellow fever dengue type 2 (ChimeriVax-DEN2) vaccine: Phase I clinical trial for safety and immunogenicity: effect of yellow fever pre-immunity in induction of cross neutralizing antibody responses to all 4 dengue serotypes.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.10.078

7 January 2021

Evaluation of interferences between dengue vaccine serotypes in a monkey model.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.10.078

7 January 2021

Gene vaccination: plasmid DNA is more than just a blueprint

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.10.078

7 January 2021

Protection against dengue virus by non-replicating and live attenuated vaccines used together in a prime boost vaccination strategy

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.10.078

7 January 2021

Dengue tetravalent DNA vaccine increases its immunogenicity in mice when mixed with a dengue type 2 subunit vaccine or an inactivated Japanese encephalitis vaccine.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.10.078

7 January 2021

A chimeric tetravalent dengue DNA vaccine elicits neutralizing antibody to all four virus serotypes in rhesus macaques.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.10.078

7 January 2021

Dengue and dengue haemorrhagic fever

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.10.078

7 January 2021

Progress in development of a live-attenuated, tetravalent dengue virus vaccine by the United States Army Medical Research and Materiel Command.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.10.078

7 January 2021

Vaccines for the prevention of neglected diseases--dengue fever

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.10.078

7 January 2021

DNA vaccines: a key for inducing long-term cellular immunity

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.10.078

7 January 2021

A DNA vaccine candidate expressing dengue-3 virus prM and E proteins elicits neutralizing antibodies and protects mice against lethal challenge

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.10.078

7 January 2021

Recombinant vaccinia viruses co-expressing dengue-1 glycoproteins prM and E induce neutralizing antibodies in mice

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.10.078

7 January 2021

The Murray Valley encephalitis virus prM protein confers acid resistance to virus particles and alters the expression of epitopes within the R2 domain of E glycoprotein

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.10.078

7 January 2021

Induction of protective antibodies against dengue virus by tetravalent DNA immunization of mice with domain III of the envelope protein

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.10.078

7 January 2021

Recombinant plasmid expressing a truncated dengue-2 virus E protein without co-expression of prM protein induces partial protection in mice

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.10.078

7 January 2021

Structural changes and functional control of the tick-borne encephalitis virus glycoprotein E by the heterodimeric association with protein prM

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.10.078

7 January 2021

Induction of neutralizing antibodies and T cell responses by dengue virus type 2 envelope domain III encoded by plasmid and adenoviral vectors.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.10.078

7 January 2021

An envelope domain III-based chimeric antigen produced in Pichia pastoris elicits neutralizing antibodies against all four dengue virus serotypes.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.10.078

7 January 2021

A DNA vaccine expressing dengue type 2 virus premembrane and envelope genes induces neutralizing antibody and memory B cells in mice

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.10.078

7 January 2021

DNA vaccines for flaviviruses

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.10.078

7 January 2021

Immunogenicity of dengue virus type 1 DNA vaccines expressing truncated and full length envelope protein

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.10.078

7 January 2021

Altered cytokine responses of dengue-specific CD4+ T cells to heterologous serotypes

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.10.078

7 January 2021

Evaluation of protective efficacy and immune mechanisms of using a non-structural protein NS1 in DNA vaccine against dengue 2 virus in mice

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.10.078

7 January 2021

A non mouse-adapted dengue virus strain as a new model of severe dengue infection in AG129 mice

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.10.078

7 January 2021

Multiple specificities in the murine CD4+ and CD8+ T-cell response to dengue virus

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.10.078

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1016/J.VACCINE.2010.10.078

1 reference

Europe PubMed Central

19 September 2017

1 reference

Europe PubMed Central

19 September 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q40342245&oldid=1895752711"